Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 3/20 | 0.31 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838094 | 0.79 | GRIN2D (0.40) | ADORA2AADORA1SNCADAOPARG | |
| SCHEMBL19127026 | 0.79 | KDM4E (0.46) | ADORA2AADORA1DAOPARGMAPK1 | |
| SCHEMBL23638392 | 0.79 | GRIN2D (0.40) | ADORA2AADORA1SNCADAOPARG | |
| SCHEMBL15528142 | 0.71 | DAO (0.65) | DAO | |
| SCHEMBL29837979 | 0.71 | ADORA2A (0.46) | ADORA2AADORA1DAOMAPK1TYMS | |
| SCHEMBL23638393 | 0.71 | ADORA2A (0.46) | ADORA2AADORA1DAOMAPK1TYMS | |
| SCHEMBL5076877 | 0.71 | CA12 (0.42) | ADORA2AADORA1SNCAMAPK1CA12 | |
| SCHEMBL19126483 | 0.70 | SNCA (0.39) | SNCADAOMAPK1DDO | |
| SCHEMBL14308952 | 0.69 | SNCA (0.45) | ADORA2AADORA1SNCA | |
| SCHEMBL20005058 | 0.69 | SNCA (0.42) | ADORA2AADORA1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874207-A | Bicyclic compounds as MAT2A inhibitors | 江苏先声药业有限公司 | 2022-08-09 | — | — | CN | disclosed |